# Multiple Sclerosis Treatment Devices Market

> Multiple Sclerosis Treatment Devices Market Research Report Information by Type (Primary Progressive Multiple Sclerosis (PPMS), Secondary Progressive Multiple Sclerosis (SPMS), Relapsing-remitting Multiple Sclerosis (RRMS), Clinically Isolated Syndrome (CIS)), by Treatment Devices (Electrical Stimulation Devices (Functional Electrical Stimulation (FES), Transcutaneous Electrical Nerve Stimulation (TENS)), Neurostimulation Devices (Spinal Cord Stimulation (SCS), Deep Brain Stimulation (DBS))), by End-User (Hospitals & Clinics, Ambulatory Surgical Centers) and Region (North America, Europe, Asia-Pacific, South America, Middle East & Africa) - Forecast till 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 5.08%
- **2024:** $ 0.85 Billion
- **2025:** $ 0.89 Billion
- **2035:** $ 1.47 Billion
- **Key Players:** Novartis (CH), Biogen (US), Bristol-Myers Squibb (US), Sanofi (FR), Merck KGaA (DE), Teva Pharmaceutical Industries (IL), Genzyme (US), AbbVie (US), Eisai Co., Ltd. (JP)

**Report ID:** MRFR/HC/57635-CR · **Pages:** 161 · **Author:** Rahul Gotadki · **Last Updated:** May 15, 2026

**URL:** https://www.marketresearchfuture.com/reports/multiple-sclerosis-treatment-devices-market-59406

---

## Market Summary

## **Multiple Sclerosis Treatment Devices Market Overview**

**The Multiple Sclerosis Treatment Devices Market was valued at USD 0.85 Billion in 2024. The industry is projected to grow from USD 0.88 Billion in 2025 to USD 1.46 Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 9.0% during the forecast period (2025-2035).**

The increasing prevalence of multiple sclerosis (MS) and advancements in neurostimulation and wearable technologies are driving the growth of the Multiple Sclerosis Treatment Devices Market.

As per the Analyst at MRFR, the disease is significantly more common in women, with a female-to-male ratio of nearly 3:1. This further influences market trends as gender-specific treatment approaches gain traction.

The increasing prevalence of MS is fueling demand for advanced treatment solutions, including **neurostimulation devices**, wearable rehabilitation technologies, and others. These solutions help manage symptoms such as spasticity, gait disorders, and chronic pain.

Improved diagnostic capabilities due to advancements in imaging techniques like MRI-based lesion tracking and biomarker research are leading to earlier and more accurate diagnoses. This further drives the adoption of treatment devices.

The rising global MS burden has also led to increased healthcare investments, government initiatives, and funding for innovative **medical technologies**. This positions the MS treatment devices market for sustained growth.

**FIGURE 1: MULTIPLE SCLEROSIS TREATMENT DEVICES MARKET VALUE (2019-2035) USD BILLION**

** Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review**

## **Multiple Sclerosis Treatment Devices Market Opportunity**

### **RISING COLLABORATIONS BETWEEN HEALTHCARE PROVIDERS AND TECHNOLOGY FIRMS**

The rising collaborations between healthcare providers and technology firms are playing a crucial role in advancing Multiple Sclerosis (MS) treatment devices. This leads to more effective, accessible, and patient-centric treatment solutions.

As MS is a chronic neurological disorder with progressive symptoms affecting mobility, muscle control, and neurological function, partnerships between hospitals, **medical device manufacturers**, and health-tech companies are driving innovation in neurostimulation, rehabilitation, and assistive treatment devices that improve patient outcomes.

One essential field of cooperation is developing next-generation neurostimulation devices. Healthcare providers collaborate closely with medical technology firms specializing in spinal cord stimulation, transcranial magnetic stimulation, and vagus nerve stimulation to explore non-invasive and implantable neurostimulation therapies for MS patients.

Collaborations are also driving innovation in wearable functional electrical stimulation (FES) devices, which assist MS patients with gait and mobility challenges. Medical device manufacturers are working alongside rehabilitation specialists and physiotherapists to develop smart FES systems that deliver targeted electrical impulses to weak or paralyzed muscles, improving walking ability.

For example, companies like Bioness and Ottobock have partnered with neurology-focused rehabilitation centers to introduce intelligent, sensor-based FES leg braces. These adapt to a patient’s movement patterns in real time, enhancing muscle coordination and and reducing the risk of falls.

Another significant achievement from technology-healthcare partnerships is the integration of AI-driven digital treatment platforms in MS therapy. Companies specializing in AI-based neuromodulation and remote therapy management are teaming up with neurology clinics to develop real-time patient monitoring solutions.

These solutions can track disease progression and adjust treatment parameters accordingly. For instance, NeuroMetrix, in collaboration with leading MS specialists, has developed Quell, a wearable neuromodulation device.

Quell provides adjustable, AI-driven pain relief therapy for MS patients suffering from chronic pain and muscle discomfort. Such partnerships are transforming the landscape of MS treatments, with all patients accessing up-to-date neurostimulation, rehabilitation, and assistive treatment devices, enhancing quality of life.

Increasing the adoption of AI-driven, cloud-connected, and wearable treatment devices will have healthcare providers and **technology companies** continuously working to present innovative, cost-effective, and patient-friendly solutions for the global market of MS treatments.

## **Multiple Sclerosis Treatment Devices Market Segment Insights**

### **Multiple Sclerosis Treatment Devices by Type Insights**

Based on Type, this segment includes Primary Progressive Multiple Sclerosis (PPMS), Secondary Progressive Multiple Sclerosis (SPMS), Relapsing-remitting Multiple Sclerosis (RRMS), and Clinically Isolated Syndrome (CIS). The Relapsing-remitting Multiple Sclerosis (RRMS) segment dominated the global market in 2024.

The Primary Progressive Multiple Sclerosis (PPMS) segment is projected to be the fastest-growing segment during the forecast period. This growth is attributed to increasing awareness, advancements in diagnostic techniques, and the launch of novel therapies targeting progressive forms of MS.

As treatment options evolve, demand for targeted PPMS solutions is anticipated to rise significantly.

**FIGURE 2: MULTIPLE SCLEROSIS TREATMENT DEVICES MARKET SHARE BY TYPE 2024 AND 2035 (USD BILLION)**

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

### **Multiple Sclerosis Treatment Devices by Treatment Devices Insights**

Based on Treatment Devices, this segment includes Electrical Stimulation Devices (Functional Electrical Stimulation (FES) and Transcutaneous Electrical Nerve Stimulation (TENS)), and Neurostimulation Devices (Spinal Cord Stimulation (SCS) and Deep Brain Stimulation (DBS)). The Electrical Stimulation Devices segment dominated the global market in 2024.

This segment is projected to be the fastest-growing during the forecast period. These devices enhance mobility and improve quality of life for patients, which has driven their widespread acceptance in both clinical and home care settings.

Furthermore, this segment is projected to be the fastest-growing during the forecast period, supported by technological advancements, increased investment in neuro-rehabilitation, and rising awareness of non-pharmacological interventions.

Compared to neurostimulation devices, **electrical stimulation** offers a cost-effective and accessible treatment option, contributing to its rapid growth and expanding role in MS symptom management.

### **Multiple Sclerosis Treatment Devices by End-User Insights**

Based on the End-User, this segment includes Hospitals & Clinics and Ambulatory Surgical Centers. The Hospitals & Clinics segment dominated the global market in 2024.

Hospitals and clinics serve as primary centers for diagnosis, therapy initiation, and long-term management of multiple sclerosis, driving consistent demand.

The Ambulatory Surgical Centers (ASCs) segment is projected to be the fastest-growing during the forecast period. This growth is fueled by the rising preference for minimally invasive procedures, shorter recovery times, and reduced healthcare costs associated with ASCs.

Increasing patient inclination toward outpatient care and advancements in portable treatment device technologies further support the rapid expansion of this segment in the coming years.

## **Multiple Sclerosis Treatment Devices Regional Insights**

Based on the Region, the global Multiple Sclerosis Treatment Devices are segmented into North America, Europe, Asia-Pacific, South America and Middle East & Africa. Europe dominated the global market in 2024.

The Asia-Pacific is projected to be the fastest-growing segment during the forecast period. Major demand factors driving the Europe market are the increasing prevalence of multiple sclerosis (MS) and advancements in neurostimulation and wearable technologies.

Europe dominated the global Multiple Sclerosis (MS) Treatment Devices market due to its advanced healthcare infrastructure and rising prevalence of MS. The region benefits from strong investments in research and development.

It also benefits from the growing adoption of innovative neurostimulation and wearable technologies. These advancements support more effective symptom management and improve patient quality of life, driving market growth.

Government initiatives and increased awareness of early diagnosis and **treatment options** also contribute to Europe’s leading position.

**FIGURE 3: MULTIPLE SCLEROSIS TREATMENT DEVICES MARKET VALUE BY REGION 2024 AND 2035 (USD BILLION)**

Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review

Further, the countries considered in the scope of the Application Tracking System Market are the US, Canada, Germany, France, UK, Spain, Italy, Russia, China, India, Japan, South Korea, Malaysia, Thailand, Indonesia, Brazil, Mexico, Argentina, GCC Countries, South Africa and others.

## **Global Multiple Sclerosis Treatment Devices Key Market Players & Competitive Insights**

Many global, regional, and local vendors characterize the Multiple Sclerosis Treatment Devices Market. The market is highly competitive, with all the players competing to gain market share.

Intense competition, rapid advances in technology, frequent changes in government policies, and environmental regulations are key factors that confront market growth.

The vendors compete based on cost, product quality, reliability, and government regulations. Vendors must provide cost-efficient, high-quality products to survive and succeed in an intensely competitive market.

The major competitors in the market are Enovis, Axonics, Inc., Koninklijke Philips N.V., BTL, Bayer AG, Medtronic, Abbott, Boston Scientific Corporation, Biotronik, Saluda Medical Pty Ltd, among others.

The Multiple Sclerosis Treatment Devices Market is a consolidated market due to increasing competition, acquisitions, mergers and other strategic market developments and decisions to improve operational effectiveness.

## **Key Companies in the Multiple Sclerosis Treatment Devices Market include**

- Enovis
- Axonics, Inc.
- Koninklijke Philips N.V.
- BTL
- Bayer AG
- Medtronic
- Abbott
- Boston Scientific Corporation
- Biotronik
- Saluda Medical Pty Ltd

## **Multiple Sclerosis Treatment Devices Market Industry Developments**

**August 2024** The FDA recently approved Medtronic’s closed-loop rechargeable spinal cord stimulator (SCS). This approval makes Inceptiv the first SCS device on the market with a closed-loop feature that continuously senses biological signals along the spinal cord and automatically adjusts stimulation in real time, ensuring therapy remains synchronized with patients' daily activities.

**April 2023** Biotronik announced that it received FDA approval for its Prospera Spinal Cord Stimulation (SCS) system, which features Resonance, a multiphase stimulation paradigm. The system is paired with Embrace One, a patient-centric care model that offers automatic, objective, daily remote monitoring.

**January 2021** Boston Scientific launched the WaveWriter Alpha Spinal Cord Stimulator (SCS) Systems in the U.S., offering a comprehensive portfolio of four MRI-conditional, Bluetooth-enabled implantable pulse generators (IPGs). Available in both rechargeable and non-rechargeable options.

## **Multiple Sclerosis Treatment Devices Market Segmentation**

### **Multiple Sclerosis Treatment Devices by Type Outlook**

- Primary Progressive Multiple Sclerosis (PPMS)
- Secondary Progressive Multiple Sclerosis (SPMS)
- Relapsing-remitting Multiple Sclerosis (RRMS)
- Clinically Isolated Syndrome (CIS)

### **Multiple Sclerosis Treatment Devices by Treatment Devices Outlook**

- Electrical Stimulation Devices - Functional Electrical Stimulation (FES) - Transcutaneous Electrical Nerve Stimulation (TENS)
- Neurostimulation Devices - Spinal Cord Stimulation (SCS) - Deep Brain Stimulation (DBS)

### **Multiple Sclerosis Treatment Devices by End-User Outlook**

- Hospitals & Clinics
- Ambulatory Surgical Centers

### **Multiple Sclerosis Treatment Devices Regional Outlook**

- North America - US - Canada - Mexico
- Europe - Germany - France - UK - Spain - Italy - Russia - Rest of Europe
- Asia-pacific - China - India - Japan - South Korea - Malaysia - Thailand - Indonesia - Rest of Asia-Pacific
- South America - Brazil - Mexico - Argentina - Rest of South America
- Middle East & Africa - GCC Countries - South Africa - Rest of MEA

## Market Drivers

### Growing Awareness and Education Initiatives

The increasing awareness and education initiatives surrounding multiple sclerosis are driving the Multiple Sclerosis Treatment Devices Market. Campaigns aimed at educating both healthcare professionals and the general public about MS are gaining momentum. These initiatives are crucial in promoting early diagnosis and treatment, which can significantly improve patient outcomes. As awareness grows, patients are more likely to seek out advanced treatment options, including innovative devices designed for MS management. Furthermore, educational programs are fostering a better understanding of the disease, which may lead to increased advocacy for research and development in treatment technologies. This heightened awareness is expected to contribute positively to market growth as stakeholders respond to the evolving needs of patients.

### Increasing Prevalence of Multiple Sclerosis

The rising incidence of multiple sclerosis (MS) is a pivotal driver for the Multiple Sclerosis Treatment Devices Market. Recent estimates suggest that approximately 2.3 million individuals are affected by MS worldwide, with a notable increase in diagnoses over the past decade. This growing patient population necessitates the development and availability of effective treatment devices. As awareness of MS expands, healthcare providers are more likely to invest in innovative treatment solutions, thereby propelling market growth. Furthermore, the increasing demand for personalized treatment options is likely to stimulate advancements in device technology, enhancing patient outcomes. The correlation between the prevalence of MS and the demand for treatment devices indicates a robust market potential, as stakeholders seek to address the needs of this expanding demographic.

### Regulatory Support for Innovative Treatments

Regulatory support for innovative treatment devices is a key driver in the Multiple Sclerosis Treatment Devices Market. Regulatory bodies are increasingly recognizing the need for expedited approval processes for new therapies and devices aimed at treating MS. This support is crucial in facilitating the introduction of cutting-edge technologies that can significantly enhance patient care. For instance, the implementation of fast-track designations for promising treatment devices can accelerate their availability in the market. As regulatory frameworks evolve to support innovation, manufacturers are likely to invest more in research and development, leading to a broader range of treatment options for patients. This regulatory environment is expected to foster a dynamic market landscape, encouraging the growth of the MS treatment devices sector.

### Rising Investment in Healthcare Infrastructure

The increasing investment in healthcare infrastructure is a significant driver for the Multiple Sclerosis Treatment Devices Market. Governments and private entities are allocating substantial resources to enhance healthcare facilities and improve access to treatment options for chronic conditions like MS. This trend is particularly evident in regions where healthcare systems are undergoing modernization. Enhanced infrastructure facilitates the distribution and accessibility of advanced treatment devices, thereby meeting the growing demand from patients and healthcare providers. Additionally, the establishment of specialized MS treatment centers is likely to foster innovation and collaboration among stakeholders, further propelling market growth. The commitment to improving healthcare infrastructure suggests a promising outlook for the MS treatment devices market.

### Technological Innovations in Treatment Devices

Technological advancements play a crucial role in shaping the Multiple Sclerosis Treatment Devices Market. Innovations such as wearable devices, telehealth solutions, and advanced drug delivery systems are transforming the landscape of MS treatment. For instance, the integration of artificial intelligence and machine learning in treatment devices is enhancing the precision of therapies, allowing for tailored approaches to individual patient needs. The market for these innovative devices is projected to grow significantly, with estimates indicating a compound annual growth rate (CAGR) of over 8% in the coming years. As technology continues to evolve, the potential for improved patient engagement and adherence to treatment regimens becomes increasingly apparent, further driving market expansion.

## Future Outlook

The Multiple Sclerosis Treatment Devices Market is projected to grow at a 5.08% CAGR from 2025 to 2035, driven by technological advancements, increasing patient awareness, and rising healthcare expenditures.

**New opportunities:**

- Development of portable neurostimulation devices for home use Integration of AI for personalized treatment plans Expansion into emerging markets with tailored solutions

By 2035, the market is expected to exhibit robust growth, driven by innovation and strategic expansions.

## Segment Insights

### By Type: Relapsing-remitting Multiple Sclerosis (RRMS) (Largest) vs. Primary Progressive Multiple Sclerosis (PPMS) (Fastest-Growing)

In the Multiple Sclerosis Treatment Devices Market, Relapsing-remitting Multiple Sclerosis (RRMS) holds the largest market share, predominantly driven by its prevalence and the availability of advanced therapeutic devices. Secondary Progressive Multiple Sclerosis (SPMS) follows, as a significant portion of patients transition from RRMS to this more progressive form, further necessitating treatment solutions. Following these, Primary Progressive Multiple Sclerosis (PPMS) and Clinically Isolated Syndrome (CIS) represent smaller, yet vital segments in addressing specific patient needs. Over the forecast period, the segment of Primary Progressive Multiple Sclerosis (PPMS) emerges as the fastest-growing segment, largely due to increasing recognition and diagnosis of the condition, alongside advancements in treatment technologies catering to this demographic. The demand for innovative devices aimed at progressive forms of MS is anticipated to rise, propelling overall market growth. Clinically Isolated Syndrome (CIS) continues to be relevant as early intervention strategies gain traction, influencing the treatment approach for at-risk populations.

Relapsing-remitting Multiple Sclerosis (RRMS) (Dominant) vs. Primary Progressive Multiple Sclerosis (PPMS) (Emerging)

Relapsing-remitting Multiple Sclerosis (RRMS) serves as the dominant segment in the Multiple Sclerosis Treatment Devices Market, characterized by its episodic nature and higher incidence rates among patients. The availability of a diverse array of treatment devices and the ongoing research and development efforts facilitate effective management of this variant, keeping it at the forefront of treatment options. In contrast, Primary Progressive Multiple Sclerosis (PPMS) is emerging as a critical segment due to its unique challenges and treatment needs. Patients with PPMS experience a continuous worsening of symptoms without distinct relapses, which necessitates innovative approaches in device development. As awareness grows and technology evolves, the demand for targeted therapeutic solutions for PPMS is expected to surge, marking a significant shift in the treatment landscape.

### By Treatment Devices: Electrical Stimulation Devices (Largest) vs. Neurostimulation Devices (Fastest-Growing)

The Multiple Sclerosis Treatment Devices Market sees a notable distribution in market share between Electrical Stimulation Devices and Neurostimulation Devices. Electrical Stimulation Devices currently hold the dominant position, attributed to their established effectiveness in managing symptoms like muscle spasms and coordination issues. Meanwhile, Neurostimulation Devices are rapidly gaining traction as patients increasingly seek alternative therapies, leading to a dynamic shift in preference towards these innovative solutions.

Treatment Devices: Electrical Stimulation Devices (Dominant) vs. Neurostimulation Devices (Emerging)

Electrical Stimulation Devices stand as the dominant force in the Multiple Sclerosis Treatment Devices market, renowned for their capacity to alleviate debilitating symptoms associated with the condition. These devices effectively stimulate nerves and muscles, enhancing mobility and improving quality of life for patients. In contrast, Neurostimulation Devices are emerging as a forward-thinking solution, appealing particularly to those seeking newer therapies. The rapid advancements in technology and increased focus on patient comfort and efficacy position Neurostimulation Devices as a promising area for future growth. Their potential to customize treatment and deliver targeted therapy makes them an attractive option for many patients.

### By End-User: Hospitals & Clinics (Largest) vs. Ambulatory Surgical Centers (Fastest-Growing)

In the Multiple Sclerosis Treatment Devices Market, hospitals and clinics constitute the largest segment, holding a significant share of the overall market. These institutions provide comprehensive care and access to advanced treatment devices, driving their dominance within the sector. Conversely, ambulatory surgical centers are emerging as a fast-growing segment, thanks to the increasing trend of minimally invasive procedures and outpatient treatments that appeal to both patients and practitioners seeking efficiency.

Hospitals & Clinics (Dominant) vs. Ambulatory Surgical Centers (Emerging)

The hospitals and clinics segment is characterized by its established presence and vast resources for managing multiple sclerosis patients. They typically offer a wide range of treatment options and comprehensive care plans, which contribute to their dominant market position. On the other hand, ambulatory surgical centers are capitalizing on the shift towards outpatient care. These centers are recognized for their ability to perform specialized procedures efficiently, resulting in lower costs and improved patient satisfaction. The demand for less invasive treatments is aiding their rapid growth, positioning them as an emerging force in the Multiple Sclerosis Treatment Devices Market.

## Regional Market Share Analysis

### North America : Leading Market for Innovation

North America is the largest market for Multiple Sclerosis treatment devices, holding approximately 45% of the global market share. The region benefits from advanced healthcare infrastructure, high prevalence of MS, and significant investments in research and development. Regulatory support from agencies like the FDA further catalyzes market growth, ensuring timely access to innovative therapies and devices. The United States is the primary contributor, with key players such as Biogen, AbbVie, and Novartis leading the competitive landscape. Canada also plays a significant role, with increasing awareness and healthcare initiatives aimed at improving patient outcomes. The presence of established companies and ongoing clinical trials enhances the region's attractiveness for new entrants and innovations.

### Europe : Emerging Regulatory Frameworks

Europe is the second-largest market for Multiple Sclerosis treatment devices, accounting for around 30% of the global market. The region is witnessing growth driven by supportive regulatory frameworks and increasing healthcare expenditure. Countries like Germany and France are leading in market share, bolstered by favorable reimbursement policies and a growing aging population that is more susceptible to MS. Germany stands out as a key player, with significant contributions from companies like Merck KGaA and Sanofi. The competitive landscape is characterized by a mix of established firms and innovative startups, focusing on advanced treatment options. The European Medicines Agency (EMA) plays a crucial role in ensuring the safety and efficacy of new devices, fostering a conducive environment for market expansion.

### Asia-Pacific : Rapidly Growing Market Potential

Asia-Pacific is an emerging powerhouse in the Multiple Sclerosis treatment devices market, holding about 15% of the global share. The region is characterized by increasing awareness of MS, rising healthcare investments, and a growing patient population. Countries like Japan and Australia are leading the charge, supported by government initiatives aimed at improving healthcare access and treatment options. Japan is particularly notable for its advanced healthcare system and presence of key players like Eisai Co., Ltd. and Teva Pharmaceutical Industries. The competitive landscape is evolving, with local companies increasingly entering the market, driven by innovations in treatment devices. Collaborative efforts between governments and private sectors are expected to further enhance market growth in the coming years.

### Middle East and Africa : Untapped Market Opportunities

The Middle East and Africa region represents a nascent market for Multiple Sclerosis treatment devices, holding approximately 10% of the global market share. The growth is primarily driven by increasing healthcare investments and rising awareness of MS. Countries like South Africa and the UAE are beginning to establish frameworks for better healthcare delivery, which is crucial for addressing the needs of MS patients. South Africa is emerging as a key player, with initiatives aimed at improving access to treatment and care. The competitive landscape is still developing, with opportunities for both local and international companies to introduce innovative solutions. As healthcare systems evolve, the region is poised for significant growth in the MS treatment devices market.

## Competitive Benchmarking

Many global, regional, and local vendors characterize the Multiple Sclerosis Treatment Devices Market. The market is highly competitive, with all the players competing to gain market share. Intense competition, rapid advances in technology, frequent changes in government policies, and environmental regulations are key factors that confront market growth. The vendors compete based on cost, product quality, reliability, and government regulations. Vendors must provide cost-efficient, high-quality products to survive and succeed in an intensely competitive market. The major competitors in the market are Enovis, Axonics, Inc., Koninklijke Philips N.V., BTL, Bayer AG, Medtronic, Abbott, Boston Scientific Corporation, Biotronik, Saluda Medical Pty Ltd, among others. The Multiple Sclerosis Treatment Devices Market is a consolidated market due to increasing competition, acquisitions, mergers and other strategic market developments and decisions to improve operational effectiveness.

## Recent News & Developments

**August 2024** The FDA recently approved Medtronic’s closed-loop rechargeable spinal cord stimulator (SCS). This approval makes Inceptiv the first SCS device on the market with a closed-loop feature that continuously senses biological signals along the spinal cord and automatically adjusts stimulation in real time, ensuring therapy remains synchronized with patients' daily activities.

**April 2023** Biotronik announced that it received FDA approval for its Prospera Spinal Cord Stimulation (SCS) system, which features Resonance, a multiphase stimulation paradigm. The system is paired with Embrace One, a patient-centric care model that offers automatic, objective, daily remote monitoring.

**January 2021** Boston Scientific launched the WaveWriter Alpha Spinal Cord Stimulator (SCS) Systems in the U.S., offering a comprehensive portfolio of four MRI-conditional, Bluetooth-enabled [implantable pulse generators](https://www.marketresearchfuture.com/reports/implantable-pulse-generator-market-32337)(IPGs). Available in both rechargeable and non-rechargeable options.

## Report Scope

| MARKET SIZE 2024 | 0.85(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 0.8932(USD Billion) |
| MARKET SIZE 2035 | 1.466(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 5.08% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Novartis (CH), Biogen (US), Bristol-Myers Squibb (US), Sanofi (FR), Merck KGaA (DE), Teva Pharmaceutical Industries (IL), Genzyme (US), AbbVie (US), Eisai Co., Ltd. (JP) |
| Segments Covered | Type, Treatment Devices, End-User |
| Key Market Opportunities | Integration of advanced neurostimulation technologies enhances treatment efficacy in the Multiple Sclerosis Treatment Devices Market. |
| Key Market Dynamics | Technological advancements and regulatory changes drive innovation in Multiple Sclerosis treatment devices, enhancing patient outcomes. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the projected market valuation for the Multiple Sclerosis Treatment Devices Market in 2035?**
A: The projected market valuation for the Multiple Sclerosis Treatment Devices Market in 2035 is 1.466 USD Billion.

**Q: What was the overall market valuation for the Multiple Sclerosis Treatment Devices Market in 2024?**
A: The overall market valuation for the Multiple Sclerosis Treatment Devices Market in 2024 was 0.85 USD Billion.

**Q: What is the expected CAGR for the Multiple Sclerosis Treatment Devices Market from 2025 to 2035?**
A: The expected CAGR for the Multiple Sclerosis Treatment Devices Market during the forecast period 2025 - 2035 is 5.08%.

**Q: Which companies are considered key players in the Multiple Sclerosis Treatment Devices Market?**
A: Key players in the Multiple Sclerosis Treatment Devices Market include Novartis, Biogen, Bristol-Myers Squibb, Sanofi, Merck KGaA, Teva Pharmaceutical Industries, Genzyme, AbbVie, and Eisai Co., Ltd.

**Q: What are the projected valuations for the different types of Multiple Sclerosis in 2035?**
A: In 2035, the projected valuations for Multiple Sclerosis types are: PPMS at 0.25 USD Billion, SPMS at 0.35 USD Billion, RRMS at 0.55 USD Billion, and CIS at 0.25 USD Billion.

**Q: What is the market size for Electrical Stimulation Devices in 2035?**
A: The market size for Electrical Stimulation Devices is projected to reach 0.58 USD Billion by 2035.

**Q: How does the market for Neurostimulation Devices compare to Electrical Stimulation Devices in 2035?**
A: By 2035, the market for Neurostimulation Devices is expected to be larger, reaching 0.88 USD Billion compared to 0.58 USD Billion for Electrical Stimulation Devices.

**Q: What are the projected market sizes for hospitals and clinics as end-users in 2035?**
A: In 2035, the projected market size for hospitals and clinics as end-users is 0.748 USD Billion.

**Q: What is the expected market size for Ambulatory Surgical Centers in 2035?**
A: The expected market size for Ambulatory Surgical Centers in 2035 is projected to be 0.718 USD Billion.

**Q: How do the market segments for Multiple Sclerosis Treatment Devices break down?**
A: The market segments for Multiple Sclerosis Treatment Devices include types such as PPMS, SPMS, RRMS, and CIS, along with treatment devices like Electrical and Neurostimulation Devices.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/multiple-sclerosis-treatment-devices-market-59406*